Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients.
Oku Y, Toyokawa G, Wakasu S, Kinoshita F, Takamori S, Watanabe K, Haratake N, Nagano T, Kosai K, Takada K, Fujimoto A, Higashijima K, Shiraishi Y, Tanaka K, Takeoka H, Okamoto M, Yamashita T, Shimokawa M, Shoji F, Yamazaki K, Okamoto T, Seto T, Ueda H, Takeo S, Nakashima N, Okamoto I, Takenaka T, Yoshizumi T. Oku Y, et al. Among authors: okamoto i, okamoto m, okamoto t. Cancer Med. 2023 Jul;12(13):14327-14336. doi: 10.1002/cam4.6110. Epub 2023 May 21. Cancer Med. 2023. PMID: 37211905 Free PMC article.
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T. Morita S, et al. Among authors: okamoto i. Clin Cancer Res. 2009 Jul 1;15(13):4493-8. doi: 10.1158/1078-0432.CCR-09-0391. Epub 2009 Jun 16. Clin Cancer Res. 2009. PMID: 19531624
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Mitsudomi T, et al. Among authors: okamoto i. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18. Lancet Oncol. 2010. PMID: 20022809 Clinical Trial.
S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
Ichinose Y, Seto T, Sasaki T, Yamanaka T, Okamoto I, Takeda K, Tanaka M, Katakami N, Sawa T, Kudoh S, Saka H, Nishimura Y, Nakagawa K, Fukuoka M. Ichinose Y, et al. Among authors: okamoto i. J Thorac Oncol. 2011 Dec;6(12):2069-75. doi: 10.1097/JTO.0b013e3182307e5a. J Thorac Oncol. 2011. PMID: 22052226 Free article. Clinical Trial.
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Okamoto I, Yoshioka H, Takeda K, Satouchi M, Yamamoto N, Seto T, Kasahara K, Miyazaki M, Kitamura R, Ohyama A, Hokoda N, Nakayama H, Yoshihara E, Nakagawa K. Okamoto I, et al. J Thorac Oncol. 2012 Feb;7(2):427-33. doi: 10.1097/JTO.0b013e318238154d. J Thorac Oncol. 2012. PMID: 22071785 Free article. Clinical Trial.
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K. Yoshioka H, et al. Among authors: okamoto i. Ann Oncol. 2013 May;24(5):1326-31. doi: 10.1093/annonc/mds629. Epub 2012 Dec 30. Ann Oncol. 2013. PMID: 23277482 Free article. Clinical Trial.
Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M. Urata Y, et al. Among authors: okamoto i. Cancer. 2013 Jun 15;119(12):2275-81. doi: 10.1002/cncr.28048. Epub 2013 Apr 4. Cancer. 2013. PMID: 23558513 Free article. Clinical Trial.
719 results